Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas

Abstract 18F-FDG PET/CT is recommended for staging and response assessment in FDG-avid lymphomas, such as HL and DLBCL. But evidence of PET/CT regarding T-cell lymphomas (TCLs) was limited. In this retrospective study, we conducted survival analysis using interim PET/CT in 51 TCLs patients. PET/CT were reported using the Deauville 5-point score (DS) and the ΔSUVmax. In univariate analysis, I-PET/CT had a significant prognostic value of survival outcomes based on DS (p < .001 for progression-free survival (PFS), p = .010 for overall survival (OS)) and ΔSUVmax (p < .001 for PFS, p = .023 for OS). In multivariate analysis, DS remained a statistically independent predictor of PFS (p < .001) and OS (p = .017). ΔSUVmax remained a statistically independent predictor of PFS (p = .008), but not of OS (p = 0.311). Therefore, DS on I-PET/CT had a remarkable value of predicting survival outcomes in TCLs.

[1]  Sang Eun Kim,et al.  Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores , 2018, Leukemia & lymphoma.

[2]  John O. Prior,et al.  Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients , 2017, The Journal of Nuclear Medicine.

[3]  Kyung-Han Lee,et al.  Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma , 2017, Leukemia & lymphoma.

[4]  F. d'Amore,et al.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. , 2016, Blood.

[5]  M. Bøgsted,et al.  Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients , 2015, American journal of hematology.

[6]  R. Tian,et al.  The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma , 2015, Clinical nuclear medicine.

[7]  J. Min,et al.  Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma , 2015, BMC Cancer.

[8]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Khong,et al.  Midtreatment 18F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center , 2014, The Journal of Nuclear Medicine.

[11]  A. Gallamini,et al.  Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? , 2012, Blood.

[12]  J. Choi,et al.  The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma , 2012, American journal of hematology.

[13]  S. Barrington,et al.  Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus , 2012, Leukemia & lymphoma.

[14]  S. Ferrero,et al.  Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.

[15]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[16]  J. Min,et al.  Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. , 2011, European journal of cancer.

[17]  Bruce D Cheson,et al.  Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Ora Israel,et al.  18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.

[19]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[20]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Wahl,et al.  FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma , 2008, Current opinion in oncology.

[22]  B. Cheson,et al.  The role of FDG-PET scans in patients with lymphoma. , 2007, Blood.

[23]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[24]  K. Ohtomo,et al.  FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[28]  A. Zelenetz,et al.  F-fl uorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma , 2013 .

[29]  C. Bodet-Milin,et al.  F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group , 2011 .

[30]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[31]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.